Annalisa Capuano

Annalisa Capuano

Auto-generated profile, based on publicly available information

Annalisa Capuano

Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Second University of Naples, 80131, Naples, Italy

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2013 in Endocrine
Verified
Journal Article
Closed access
PDF file
KEKatherine Esposito
Katherine Esposito
PCPaolo Chiodini
Paolo Chiodini
ACAnnalisa Capuano
Annalisa Capuano
GBGiuseppe Bellastella
Giuseppe Bellastella
Maria Ida MaiorinoMaria Ida Maiorino
Maria Ida Maiorino
DGDario Giugliano
Dario Giugliano

1 March 2006 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
Silvia SchenoneSilvia Schenone
Silvia Schenone
Chiara BrulloChiara Brullo
Chiara Brullo
OBOlga Bruno
Olga Bruno
FBFrancesco Bondavalli
Francesco Bondavalli
ARAngelo Ranise
Angelo Ranise
GFGiuseppe Falcone
Giuseppe Falcone

3 May 2013 in Endocrine
Verified
Journal Article
Closed access
PDF file
KEKatherine Esposito
Katherine Esposito
PCPaolo Chiodini
Paolo Chiodini
ACAnnalisa Capuano
Annalisa Capuano
GBGiuseppe Bellastella
Giuseppe Bellastella
Maria Ida MaiorinoMaria Ida Maiorino
Maria Ida Maiorino
DGDario Giugliano
Dario Giugliano

1 December 2013 in Menopause
Verified
Journal Article
Closed access
KEKatherine Esposito
Katherine Esposito
PCPaolo Chiodini
Paolo Chiodini
ACAnnalisa Capuano
Annalisa Capuano
GBGiuseppe Bellastella
Giuseppe Bellastella
Maria Ida MaiorinoMaria Ida Maiorino
Maria Ida Maiorino
DGDario Giugliano
Dario Giugliano
The role of metabolic syndrome (MS) and its individual components in postmenopausal breast cancer (PBC) risk is still unclear. We reviewed and summarized epidemiological studies assessing the association of MS with the risk of PBC. We conducted an electronic search, without restrictions, for articles published before October 31, 2012. Every included study was to report risk estimates with 95% CIs for the association between MS and PBC. Study-specific estimates were pooled using random-effects models. Nine articles (with 6,417 cancer cases), all published in English, were included in the meta-analysis. MS was associated with a 52% increase in cancer risk (P < 0.001)-for the most part confined to noncohort studies (109% increased risk); the risk estimates changed little, depending on populations (United States and Europe) and definition of the syndrome (traditional vs nontraditional). The risk estimates for PBC were 1.12 (P = 0.068) for higher values of body mass index/waist circumference, 1.19 (P = 0.005) for hyperglycemia (higher fasting glucose or diabetes), 1.13 (P = 0.027) for higher blood pressure, 1.08 (P = 0.248) for higher triglycerides, and 1.39 (P = 0.008) for lower high-density lipoprotein cholesterol. All these estimates were lower than those associated with MS in the same studies. MS is associated with a moderately increased risk of PBC. No single component explains the risk conveyed by the full syndrome.

1 September 2013 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
DGDario Giugliano
Dario Giugliano
LSLiberata Sportiello
Liberata Sportiello
ACAnnalisa Capuano
Annalisa Capuano
Maria Ida MaiorinoMaria Ida Maiorino
Maria Ida Maiorino
FRFrancesco Rossi
Francesco Rossi
KEKatherine Esposito
Katherine Esposito
Peer reviewed article authored by (Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K). Read article or submit your manuscript for publishing.

16 February 2015 in BMJ Open
Verified
Journal Article
Open access
PDF file
KEKatherine Esposito
Katherine Esposito
PCPaolo Chiodini
Paolo Chiodini
Maria Ida MaiorinoMaria Ida Maiorino
Maria Ida Maiorino
ACAnnalisa Capuano
Annalisa Capuano
DCDomenico Cozzolino
Domenico Cozzolino
DGDario Giugliano
Dario Giugliano
Objectives: To develop a nomogram for estimating the glycated haemoglobin (HbA1c) response to different dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes.Design: A systematic review and meta-analysis of randomised controlled trials (RCTs) of DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, linagliptin and alogliptin) on HbA1c were conducted. Electronic searches were carried out up to December 2013. Trials were included if they were carried out on participants with type 2 diabetes, lasted at least 12 weeks, included at least 30 participants and had a final assessment of HbA1c. A random effect model was used to pool data. A nomogram was used to represent results of the metaregression model.Participants: Adults with type 2 diabetes.Interventions: Any DPP-4 inhibitor (vildagliptin, sitagliptin, saxagliptin, linagliptin or alogliptin).Outcome measures: The HbA1c response to each DPP-4 inhibitor within 1 year of therapy.Results: We screened 928 citations and reviewed 98 articles reporting 98 RCTs with 100 arms in 24 163 participants. There were 26 arms with vildagliptin, 37 with sitagliptin, 13 with saxagliptin, 13 with linagliptin and 11 with alogliptin. For all 100 arms, the mean baseline HbA1c value was 8.05% (64 mmol/mol); the decrease of HbA1c from baseline was −0.77% (95% CI −0.82 to −0.72%), with high heterogeneity (I2=96%). Multivariable metaregression model that included baseline HbA1c, type of DPP-4 inhibitor and fasting glucose explained 58% of variance between studies, with no significant interaction between them. Other factors, including age, previous diabetes drugs and duration of treatment added low predictive power (<1%). The nomogram estimates the absolute HbA1c reduction from baseline using the type of DPP-4 inhibitor, baseline values of HbA1c and fasting glucose.Conclusions: Baseline HbA1c level and fasting glucose explain most of the variance in HbA1c change in response to DPP-4 inhibitors: each increase of 1.0% units HbA1c provides a 0.4–0.5% units greater fall.